Product
FVIII
2 clinical trials
2 indications
Indication
Hemophilia AIndication
Immune ToleranceClinical trial
A Multi-center, Prospective Study Evaluating the Rate of Inhibitor Recurrence Following Successful ITI in Patients Receiving Ongoing Once Per Weekly Factor VIII Therapy Along With Emicizumab and in Patients Who Discontinue FVIII Therapy and Are on Emicizumab for ProphylaxisStatus: Active (not recruiting), Estimated PCD: 2024-09-20
Clinical trial
Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis -STEP: SporTs Emicizumab ProphylaxisStatus: Recruiting, Estimated PCD: 2027-12-01